New-to-Nature Medicines
We use synthetic biology and directed evolution
to engineer natural product drugs
for unmet medical needs.
Myria Biosciences pioneers a new drug class, GEMMS: Genetically Engineered Modular Molecule Scaffolds).
GEMMS are ideally suited to address recalcitrant, or “undruggable” targets.
A new golden age of natural products is here.
Last century’s classic natural product discovery for pharma applications brought treasures like penicillin, cyclosporin, rapamycin, and statins.
Genome sequencing gave us insight into biosynthetic gene clusters and paved the way for attempts at production in heterologous host cells.